https://scholars.lib.ntu.edu.tw/handle/123456789/630431
標題: | Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial | 作者: | CHEN-HUA LIU Huang, Chung-Feng CHUN-JEN LIU Dai, Chia-Yen Huang, Jee-Fu JOU-WEI LIN Liang, Cheng-Chao Yang, Sheng-Shun Lin, Chih-Lin TUNG-HUNG SU HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN Chuang, Wan-Long JIA-HORNG KAO Yu, Ming-Lung |
關鍵字: | 28B GENETIC POLYMORPHISMS; TREATMENT DURATION; COMBINATION THERAPY; ANTIVIRAL TREATMENT; GUIDED THERAPY; ASIAN PATIENTS; SOFOSBUVIR; INFECTION; ALPHA-2A; FIBROSIS | 公開日期: | 1-七月-2015 | 出版社: | NATURE PUBLISHING GROUP | 卷: | 5 | 期: | 1 | 起(迄)頁: | 11710 | 來源出版物: | Scientific reports | 摘要: | Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-naïve HCV-2 patients not achieving rapid virologic response (RVR) by Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000-1,200 mg/day, cutoff body weight of 75 kg) were randomly assigned to receive a total duration of 48 (n = 94) or 24 (n = 93) weeks of therapy. The primary endpoint was sustained virologic response (SVR). Baseline patient characteristics to predict SVR were analyzed. Patients receiving 48 weeks of treatment had a greater SVR rate than those receiving 24 weeks of treatment (70.2% versus 46.2%, P = 0.001). Compared to patients treated for 24 weeks, the SVR rate in those treated for 48 weeks increased by 10.9% [95% CI: -5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had IL-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction P = 0.002). In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-naïve HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630431 | ISSN: | 2045-2322 | DOI: | 10.1038/srep11710 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。